Climb Bio Stock Technical Analysis
| CLYM Stock | 5.61 0.06 1.06% |
As of the 19th of February, Climb Bio shows the Mean Deviation of 6.41, downside deviation of 5.84, and Risk Adjusted Performance of 0.1944. Climb Bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Climb Bio information ratio, as well as the relationship between the potential upside and kurtosis to decide if Climb Bio is priced correctly, providing market reflects its regular price of 5.61 per share. Given that Climb Bio has jensen alpha of 2.04, we suggest you to validate Climb Bio's prevailing market performance to make sure the company can sustain itself at a future point.
Climb Bio Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Climb, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to ClimbClimb Bio's Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Climb Bio Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 11.43 | Strong Buy | 2 | Odds |
Most Climb analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Climb stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Climb Bio, talking to its executives and customers, or listening to Climb conference calls.
Will Biotechnology sector continue expanding? Could Climb diversify its offerings? Factors like these will boost the valuation of Climb Bio. Projected growth potential of Climb fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Climb Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Climb Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Climb Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Climb Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Climb Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Climb Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Climb Bio.
| 11/21/2025 |
| 02/19/2026 |
If you would invest 0.00 in Climb Bio on November 21, 2025 and sell it all today you would earn a total of 0.00 from holding Climb Bio or generate 0.0% return on investment in Climb Bio over 90 days. Climb Bio is related to or competes with Entera Bio, Spero Therapeutics, Seres Therapeutics, Anixa Biosciences, Acumen Pharmaceuticals, Inovio Pharmaceuticals, and Actuate Therapeutics. Climb Bio is entity of United States. It is traded as Stock on NASDAQ exchange. More
Climb Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Climb Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Climb Bio upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.84 | |||
| Information Ratio | 0.2286 | |||
| Maximum Drawdown | 42.56 | |||
| Value At Risk | (8.38) | |||
| Potential Upside | 16.99 |
Climb Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Climb Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Climb Bio's standard deviation. In reality, there are many statistical measures that can use Climb Bio historical prices to predict the future Climb Bio's volatility.| Risk Adjusted Performance | 0.1944 | |||
| Jensen Alpha | 2.04 | |||
| Total Risk Alpha | 1.58 | |||
| Sortino Ratio | 0.3318 | |||
| Treynor Ratio | (1.09) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Climb Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Climb Bio February 19, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1944 | |||
| Market Risk Adjusted Performance | (1.08) | |||
| Mean Deviation | 6.41 | |||
| Semi Deviation | 5.07 | |||
| Downside Deviation | 5.84 | |||
| Coefficient Of Variation | 427.12 | |||
| Standard Deviation | 8.48 | |||
| Variance | 71.84 | |||
| Information Ratio | 0.2286 | |||
| Jensen Alpha | 2.04 | |||
| Total Risk Alpha | 1.58 | |||
| Sortino Ratio | 0.3318 | |||
| Treynor Ratio | (1.09) | |||
| Maximum Drawdown | 42.56 | |||
| Value At Risk | (8.38) | |||
| Potential Upside | 16.99 | |||
| Downside Variance | 34.11 | |||
| Semi Variance | 25.74 | |||
| Expected Short fall | (7.91) | |||
| Skewness | 1.1 | |||
| Kurtosis | 1.68 |
Climb Bio Backtested Returns
Climb Bio is risky given 3 months investment horizon. Climb Bio secures Sharpe Ratio (or Efficiency) of 0.27, which signifies that the company had a 0.27 % return per unit of risk over the last 3 months. We have analyzed and interpolated thirty different technical indicators, which can help you to evaluate if expected returns of 2.4% are justified by taking the suggested risk. Use Climb Bio Downside Deviation of 5.84, mean deviation of 6.41, and Risk Adjusted Performance of 0.1944 to evaluate company specific risk that cannot be diversified away. Climb Bio holds a performance score of 21 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -1.81, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Climb Bio are expected to decrease by larger amounts. On the other hand, during market turmoil, Climb Bio is expected to outperform it. Use Climb Bio potential upside, and the relationship between the total risk alpha and kurtosis , to analyze future returns on Climb Bio.
Auto-correlation | 0.69 |
Good predictability
Climb Bio has good predictability. Overlapping area represents the amount of predictability between Climb Bio time series from 21st of November 2025 to 5th of January 2026 and 5th of January 2026 to 19th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Climb Bio price movement. The serial correlation of 0.69 indicates that around 69.0% of current Climb Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.69 | |
| Spearman Rank Test | 0.57 | |
| Residual Average | 0.0 | |
| Price Variance | 0.34 |
Climb Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Climb Bio Technical Analysis
The output start index for this execution was ten with a total number of output elements of fifty-one. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Climb Bio volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Climb Bio Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Climb Bio on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Climb Bio based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Climb Bio price pattern first instead of the macroeconomic environment surrounding Climb Bio. By analyzing Climb Bio's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Climb Bio's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Climb Bio specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 38.92 | 31.41 | 28.27 | 20.18 | Net Debt To EBITDA | 2.3 | 2.86 | 3.28 | 2.51 |
Climb Bio February 19, 2026 Technical Indicators
Most technical analysis of Climb help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Climb from various momentum indicators to cycle indicators. When you analyze Climb charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1944 | |||
| Market Risk Adjusted Performance | (1.08) | |||
| Mean Deviation | 6.41 | |||
| Semi Deviation | 5.07 | |||
| Downside Deviation | 5.84 | |||
| Coefficient Of Variation | 427.12 | |||
| Standard Deviation | 8.48 | |||
| Variance | 71.84 | |||
| Information Ratio | 0.2286 | |||
| Jensen Alpha | 2.04 | |||
| Total Risk Alpha | 1.58 | |||
| Sortino Ratio | 0.3318 | |||
| Treynor Ratio | (1.09) | |||
| Maximum Drawdown | 42.56 | |||
| Value At Risk | (8.38) | |||
| Potential Upside | 16.99 | |||
| Downside Variance | 34.11 | |||
| Semi Variance | 25.74 | |||
| Expected Short fall | (7.91) | |||
| Skewness | 1.1 | |||
| Kurtosis | 1.68 |
Climb Bio February 19, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Climb stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.11 | ||
| Daily Balance Of Power | (0.10) | ||
| Rate Of Daily Change | 0.99 | ||
| Day Median Price | 5.47 | ||
| Day Typical Price | 5.52 | ||
| Price Action Indicator | 0.11 | ||
| Market Facilitation Index | 0.62 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Will Biotechnology sector continue expanding? Could Climb diversify its offerings? Factors like these will boost the valuation of Climb Bio. Projected growth potential of Climb fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Climb Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Climb Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Climb Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Climb Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.